Possible Side Effects of EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin) (Table Version Date: July 28, 2022)

№ lp_2_3_60812

File format: docx Character count: 2993 File size: 31 KB

Year: 2022

Region / City: N/A

Topic: Health / Medical

Document Type: Informational

Author: N/A

Target Audience: Patients, Healthcare Professionals

Effective Period: N/A

Approval Date: N/A

Revision Date: N/A

Description: A list of possible side effects for the chemotherapy regimen EPOCH, including common, occasional, and rare side effects.

By placing an order, you agree to the Terms of Use and acknowledge that access to digital materials is provided after payment and is non-refundable, except in cases where the material is not actually accessible.

Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:

Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
In the app, tap Send.
Select network, paste our wallet address.
Send the exact amount shown above.

After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.

Array Data of Apoptosis-Related Proteins in Acute Leukemia Cells Treated with Apigenin, Etoposide, and Cyclophosphamide

Year: 2013–2019

Cell Type: THP-1 acute myeloid leukemia; Jurkat acute lymphoid leukemia

Treatment: Apigenin (AP), Etoposide (ETP), Cyclophosphamide (CYCLO)

Assay Method: Proteome ProfilerTM - Human Apoptosis Array

Measured Proteins: BAD, BAX, BCL2, BCLX, CYT c, SMAC/DIBALO, HTRA2/OMI, TRAILR1/DR4, TNFR1/TNFRSF1A, FAS/D95, FADD, CASP-3

Exposure Time: 24 hours

Effect Type: Synergistic increase or decrease in apoptosis-related protein expression

Reference Studies: Mahbub et al., 2013; 2015; 2019

Data Format: Supplementary Figures

Possible Side Effects of Dactinomycin, Vincristine (Table Version Date: June 10, 2022)

Year: 2022

Region / city: N/A

Theme: Medical information, side effects

Document type: Medical leaflet

Author: N/A

Target audience: Patients receiving Dactinomycin and Vincristine

Period of validity: N/A

Approval date: N/A

Modification date: N/A

Topics: Prednisone Etoposide Vincristine

The project is focused on storing and searching highly specialized data that is rarely indexed by major search engines.

The content of this website is protected under applicable copyright laws, including but not limited to the Copyright Act and relevant legislation of the European Union. Any use of the content, including reproduction, distribution, public communication, modification, or other processing, is prohibited without the prior written consent of the rights holder, unless expressly permitted by law. Users are permitted to use the content solely for personal purposes within the scope defined by copyright legislation. Any other use, including commercial use, requires the prior written authorization of the rights holder. Trademarks, trade names, logos, and other identifiers displayed on this website may be registered trademarks of their respective owners. Any use without the authorization of the relevant rights holder is prohibited. The website operator does not guarantee the accuracy, completeness, or timeliness of the information provided and shall not be liable for any damage or loss resulting from its use, except where required by mandatory legal provisions.

Reproduction of materials is permitted only if a link to speakdot.com is included.